

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2	wo-9805792-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:04
L2	65	jockers.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:05
L3	438	couturier.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:05
L4	1089	uhlmann.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:05
L5	8	l2 and (ob-rgrp or ob or rgrp or leptin)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:08
L6	2	l5 and antisense	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:08
L7	10	l3 and (ob-rgrp or ob or rgrp or leptin)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:11
L8	2	l7 and antisense	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:09
L9	8	l4 and (ob-rgrp or ob or rgrp or leptin)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:18
L10	89	ob-rgrp or ob adj rgrp	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:10

L11	138	bailleul.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:10
L12	2	L11 and L10	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:10
L13	0	L12 and antisense	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:10
L14	4	L11 and leptin	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:10
L15	2	L14 and antisense	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:10
L16	309786	(ob-rgrp or ob or rgrp or leptin)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:11
L17	62427	antisense sirna ribozyme	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:11
L18	3091	l17 and l16	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2005/09/01 11:12
L19	2156	inhibition gene expression and l18	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2005/09/01 11:12
L20	172	l19 and @py<"2002"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2005/09/01 11:14

L21	1160	l18 not ob	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2005/09/01 11:14
L22	44	l21 and l19 and @py<"2002"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:15
L23	86	ob-rgrp and (antisense or sirna)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:18
S1	7	"925302".ap.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 09:04
S3	89	ob-rgrp or ob adj rgrp	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/08/31 10:40
S4	138	bailleul.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/08/31 10:41
S5	2	S4 and S3	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:10
S6	4	S4 and leptin	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/08/31 11:13

PASSWORD:  
TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAPLUS and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAPLUS
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	20	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	21	JUN 13	FRFULL enhanced with patent drawing images
NEWS	22	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
NEWS	23	JUL 01	MEDICONF removed from STN
NEWS	24	JUL 07	STN Patent Forums to be held in July 2005
NEWS	25	JUL 13	SCISEARCH reloaded
NEWS	26	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS	27	AUG 11	Derwent World Patents Index(R) web-based training during August
NEWS	28	AUG 11	STN AnaVist workshops to be held in North America
NEWS	29	AUG 30	CA/CAPLUS - Increased access to 19th century research documents
NEWS	30	AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS EXPRESS			JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:26:51 ON 01 SEP 2005

=> file medline biosis caplus embase  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 11:27:12 ON 01 SEP 2005

FILE 'BIOSIS' ENTERED AT 11:27:12 ON 01 SEP 2005  
Copyright (c) 2005 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 11:27:12 ON 01 SEP 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 11:27:12 ON 01 SEP 2005  
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

=> e couturier/au

E1	2	COUTURIE S/AU
E2	1	COUTURIE STEPHEN HENRY/AU
E3	6 -->	COUTURIER/AU
E4	120	COUTURIER A/AU
E5	1	COUTURIER A J/AU
E6	3	COUTURIER ALAIN/AU
E7	1	COUTURIER ALAIN J/AU
E8	2	COUTURIER ALBERT/AU
E9	8	COUTURIER ALEXIA/AU
E10	22	COUTURIER ANDRE/AU
E11	5	COUTURIER ANDREA/AU
E12	19	COUTURIER ANNE/AU

=> e

E13	1	COUTURIER AUDREY/AU
E14	10	COUTURIER B/AU
E15	1	COUTURIER BERNARD/AU
E16	2	COUTURIER BERTRAND/AU
E17	6	COUTURIER BHAUD Y/AU
E18	131	COUTURIER C/AU
E19	4	COUTURIER C A/AU
E20	2	COUTURIER C P/AU
E21	3	COUTURIER C Y/AU
E22	1	COUTURIER C Y R/AU
E23	3	COUTURIER CATHERINE/AU
E24	3	COUTURIER CEDRIC/AU

=> e

E25	1	COUTURIER CELINE/AU
E26	4	COUTURIER CH/AU
E27	3	COUTURIER CHRISTIAN/AU
E28	6	COUTURIER CHRISTINE/AU
E29	5	COUTURIER CYR/AU
E30	16	COUTURIER CYRIL/AU
E31	563	COUTURIER D/AU
E32	1	COUTURIER D E/AU
E33	172	COUTURIER DANIEL/AU
E34	1	COUTURIER DANIEL C/AU
E35	1	COUTURIER DONALD I/AU

E36 182 COUTURIER E/AU

=> s e18 and e30

L1 0 "COUTURIER C"/AU AND "COUTURIER CYRIL"/AU

=> s e18,30

L2 0 E18,30

=> s e18;e30

L3 131 "COUTURIER C"/AU

E30 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> s e18 or e30

L4 147 "COUTURIER C"/AU OR "COUTURIER CYRIL"/AU

=> dup rem l4

PROCESSING COMPLETED FOR L4

L5 93 DUP REM L4 (54 DUPLICATES REMOVED)

=> s l5 and leptin and antisense

L6 1 L5 AND LEPTIN AND ANTISENSE

=> dis ti so au kwic

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN

TI **Antisense** oligonucleotides inhibiting expression of OB-RGRP  
protein and method for identifying compounds modifying OB-RGRP protein-  
**leptin** receptor interaction

SO Fr. Demande, 104 pp.

CODEN: FRXXBL

IN Jockers, Ralf; **Couturier, Cyril**; Uhlmann, Eugen

TI **Antisense** oligonucleotides inhibiting expression of OB-RGRP  
protein and method for identifying compounds modifying OB-RGRP protein-  
**leptin** receptor interaction

IN Jockers, Ralf; **Couturier, Cyril**; Uhlmann, Eugen

AB **Antisense** oligonucleotides inhibiting expression of the gene  
encoding the OB-RGRP (Ob receptor gene-related protein) protein and their  
uses for the prevention and/or treatment of pathologies related to  
**leptin**. A method for identifying compds. modifying the  
interaction between OB-RGRP and the **leptin** receptor is also  
disclosed. This method comprises uses of OB-RGRP and **leptin**  
receptor fusion proteins with proteins such as luciferase and YFP (a  
mutant of GFP) and measurement of the transfer of energy between these  
fusion proteins. Thus, in cells expressing OB-RGRP and treated with  
OB-RGRP **antisense** oligonucleotide the basal and **leptin**  
-stimulated signaling by **leptin** receptor was enhanced.

Interaction of **leptin** receptor and OB-RGRP was detected by  
bioluminescence resonance energy transfer in cells coexpressing  
**leptin** receptor-luciferase and OB-RGRP-YFP fusion proteins.

ST **antisense** oligonucleotide siRNA **leptin** receptor  
related protein OB RGRP; drug screening fusion protein **leptin**  
receptor luciferase OBRGRP YFP

IT **Antisense** oligonucleotides

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(2'-O-methylnucleoside-containing; **antisense** oligonucleotides  
inhibiting expression of OB-RGRP protein and method for identifying  
compds. modifying OB-RGRP protein-**leptin** receptor  
interaction)

IT Proteins

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)



(EYFP, fusion with **leptin** receptor or OB-RGRP;  
**antisense** oligonucleotides inhibiting expression of OB-RGRP  
protein and method for identifying compds. modifying OB-RGRP protein-  
**leptin** receptor interaction)

IT Proteins  
RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical  
study); USES (Uses)  
(OB-RGRP (**leptin** receptor gene-related protein), fusion with  
fluorescent proteins; **antisense** oligonucleotides inhibiting  
expression of OB-RGRP protein and method for identifying compds.  
modifying OB-RGRP protein-**leptin** receptor interaction)

IT Proteins  
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)  
(Topaz, fusion with **leptin** receptor or OB-RGRP;  
**antisense** oligonucleotides inhibiting expression of OB-RGRP  
protein and method for identifying compds. modifying OB-RGRP protein-  
**leptin** receptor interaction)

IT Drug screening  
Human  
(**antisense** oligonucleotides inhibiting expression of OB-RGRP  
protein and method for identifying compds. modifying OB-RGRP protein-  
**leptin** receptor interaction)

IT **Antisense** oligonucleotides  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(**antisense** oligonucleotides inhibiting expression of OB-RGRP  
protein and method for identifying compds. modifying OB-RGRP protein-  
**leptin** receptor interaction)

IT Resonance energy transfer  
(bioluminescence; **antisense** oligonucleotides inhibiting  
expression of OB-RGRP protein and method for identifying compds.  
modifying OB-RGRP protein-**leptin** receptor interaction)

IT DNA sequences  
(for human **leptin** receptor and OB-RGRP protein fused to  
fluorescent protein YFP or luciferase)

IT **Leptin** receptors  
RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical  
study); USES (Uses)  
(fusion with fluorescent proteins; **antisense** oligonucleotides  
inhibiting expression of OB-RGRP protein and method for identifying  
compds. modifying OB-RGRP protein-**leptin** receptor  
interaction)

IT Proteins  
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)  
(green fluorescent, GFPS65T, fusion with **leptin** receptor or  
OB-RGRP; **antisense** oligonucleotides inhibiting expression of  
OB-RGRP protein and method for identifying compds. modifying OB-RGRP  
protein-**leptin** receptor interaction)

IT Proteins  
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)  
(green fluorescent, fusion with **leptin** receptor or OB-RGRP;  
**antisense** oligonucleotides inhibiting expression of OB-RGRP  
protein and method for identifying compds. modifying OB-RGRP protein-  
**leptin** receptor interaction)

IT Post-transcriptional processing  
(interference; **antisense** oligonucleotides inhibiting  
expression of OB-RGRP protein and method for identifying compds.  
modifying OB-RGRP protein-**leptin** receptor interaction)

IT Protein sequences  
(of human **leptin** receptor and OB-RGRP protein fused to  
fluorescent protein YFP or luciferase)

IT **Antisense** oligonucleotides  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(phosphorothioate-linked; **antisense** oligonucleotides  
inhibiting expression of OB-RGRP protein and method for identifying  
compds. modifying OB-RGRP protein-**leptin** receptor

interaction)

IT Double stranded RNA  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (small interfering; **antisense** oligonucleotides inhibiting  
 expression of OB-RGRP protein and method for identifying compds.  
 modifying OB-RGRP protein-**leptin** receptor interaction)

IT **Antisense** oligonucleotides  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (triethylene glycol-terminated; **antisense** oligonucleotides  
 inhibiting expression of OB-RGRP protein and method for identifying  
 compds. modifying OB-RGRP protein-**leptin** receptor  
 interaction)

IT Proteins  
 RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical  
 study); USES (Uses)  
 (yellow fluorescent, fusion with **leptin** receptor or OB-RGRP;  
**antisense** oligonucleotides inhibiting expression of OB-RGRP  
 protein and method for identifying compds. modifying OB-RGRP protein-  
**leptin** receptor interaction)

IT 736653-92-2  
 RL: BSU (Biological study, unclassified); PRP (Properties); THU  
 (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (OB-RGRP **antisense** oligonucleotide; **antisense**  
 oligonucleotides inhibiting expression of OB-RGRP protein and method  
 for identifying compds. modifying OB-RGRP protein-**leptin**  
 receptor interaction)

IT 737464-32-3  
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES  
 (Uses)  
 (OB-RGRP **antisense** oligonucleotide; **antisense**  
 oligonucleotides inhibiting expression of OB-RGRP protein and method  
 for identifying compds. modifying OB-RGRP protein-**leptin**  
 receptor interaction)

IT 737464-35-6 737464-37-8 737464-39-0 737464-41-4 737464-44-7  
 737464-46-9  
 RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical  
 study); USES (Uses)  
 (amino acid sequence; **antisense** oligonucleotides inhibiting  
 expression of OB-RGRP protein and method for identifying compds.  
 modifying OB-RGRP protein-**leptin** receptor interaction)

IT 737464-33-4 737464-42-5, Protein MY47 (human)  
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL  
 (Biological study)  
 (amino acid sequence; **antisense** oligonucleotides inhibiting  
 expression of OB-RGRP protein and method for identifying compds.  
 modifying OB-RGRP protein-**leptin** receptor interaction)

IT 9014-00-0D, Luciferase, fusion with **leptin** receptor or OB-RGRP  
 RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical  
 study); USES (Uses)  
 (**antisense** oligonucleotides inhibiting expression of OB-RGRP  
 protein and method for identifying compds. modifying OB-RGRP protein-  
**leptin** receptor interaction)

IT 737464-31-2  
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL  
 (Biological study)  
 (nucleotide sequence; **antisense** oligonucleotides inhibiting  
 expression of OB-RGRP protein and method for identifying compds.  
 modifying OB-RGRP protein-**leptin** receptor interaction)

IT 737464-34-5 737464-36-7 737464-38-9 737464-40-3 737464-43-6  
 737464-45-8 737464-47-0  
 RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological  
 study); USES (Uses)  
 (nucleotide sequence; **antisense** oligonucleotides inhibiting  
 expression of OB-RGRP protein and method for identifying compds.  
 modifying OB-RGRP protein-**leptin** receptor interaction)



IT 737464-74-3, 3: PN: FR2850971 SEQID: 3 unclaimed DNA 737464-75-4, 9: PN: FR2850971 SEQID: 9 unclaimed DNA 737464-77-6  
 RL: PRP (Properties)  
 (unclaimed nucleotide sequence; **antisense** oligonucleotides inhibiting expression of OB-RGRP protein and method for identifying compds. modifying OB-RGRP protein-**leptin** receptor interaction)

IT 737464-76-5  
 RL: PRP (Properties)  
 (unclaimed protein sequence; **antisense** oligonucleotides inhibiting expression of OB-RGRP protein and method for identifying compds. modifying OB-RGRP protein-**leptin** receptor interaction)

IT 737464-78-7 737464-79-8 737464-80-1 737464-81-2 737464-82-3  
 737464-83-4 737464-84-5 737464-85-6 737464-86-7 737464-87-8  
 737464-88-9 737464-89-0 737464-90-3 737464-91-4 737464-92-5  
 737464-93-6  
 RL: PRP (Properties)  
 (unclaimed sequence; **antisense** oligonucleotides inhibiting expression of OB-RGRP protein and method for identifying compds. modifying OB-RGRP protein-**leptin** receptor interaction)

=> dis ibib

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004:650986 CAPLUS  
 DOCUMENT NUMBER: 141:185931  
 TITLE: **Antisense** oligonucleotides inhibiting expression of OB-RGRP protein and method for identifying compounds modifying OB-RGRP protein-**leptin** receptor interaction  
 INVENTOR(S): Jockers, Ralf; Couturier, Cyril; Uhlmann, Eugen  
 PATENT ASSIGNEE(S): Aventis Pharma S. A., Fr.; Institut National de la Sante et de la Recherche Medicale INSERM  
 SOURCE: Fr. Demande, 104 pp.  
 CODEN: FRXXBL  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2850971	A1	20040813	FR 2003-1543	20030210
WO 2004072293	A2	20040826	WO 2004-FR294	20040209
WO 2004072293	A3	20040923		
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005009042	A1	20050113	US 2004-774721	20040209

PRIORITY APPLN. INFO.:

FR 2003-1543 A 20030210  
 US 2003-461005P P 20030407

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s ob-rgrp  
L7 45 OB-RGRP

=> s antisense or sirna  
L8 114357 ANTISENSE OR SIRNA

=> s 17 and 18  
L9 4 L7 AND L8

=> dup rem  
ENTER L# LIST OR (END):19  
PROCESSING COMPLETED FOR L9  
L10 4 DUP REM L9 (0 DUPLICATES REMOVED)

=> dis ti so au l10 1-4

L10 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
TI **Antisense** oligonucleotides inhibiting expression of **OB**  
**-RGRP** protein and method for identifying compounds modifying  
**OB-RGRP** protein-leptin receptor interaction  
SO Fr. Demande, 104 pp.  
CODEN: FRXXBL  
IN Jockers, Ralf; Couturier, Cyril; Uhlmann, Eugen

L10 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
TI Genes that are differentially expressed during erythropoiesis and their  
diagnostic and therapeutic uses  
SO PCT Int. Appl., 285 pp.  
CODEN: PIXXD2  
IN Brissette, William H.; Neote, Kuldeep S.; Zagouras, Panayiotis; Zenke,  
Martin; Lemke, Britt; Hacker, Christine

L10 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
TI Gene expression profiles in bone and cartilage formation and their use in  
diagnosis and treatment of disease  
SO PCT Int. Appl., 197 pp.  
CODEN: PIXXD2  
IN Clancy, Brian; Pittman, Debra M.

L10 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
TI Nucleic acid compositions, kits, and methods for identification,  
assessment, prevention, and therapy of human breast cancer  
SO PCT Int. Appl., 2674 pp.  
CODEN: PIXXD2  
IN Lillie, James; Palermo, Adam; Wang, Youzhen; Steinmann, Kathleen; Elias,  
Josh

=> dis ibib l10 2-4

L10 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2003:409169 CAPLUS  
DOCUMENT NUMBER: 138:380506  
TITLE: Genes that are differentially expressed during  
erythropoiesis and their diagnostic and therapeutic  
uses  
INVENTOR(S): Brissette, William H.; Neote, Kuldeep S.; Zagouras,  
Panayiotis; Zenke, Martin; Lemke, Britt; Hacker,  
Christine  
PATENT ASSIGNEE(S): Pfizer Products Inc., USA; Max-Delbrueck-Centrum Fuer  
Molekulare Medizin  
SOURCE: PCT Int. Appl., 285 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003038130	A2	20030508	WO 2002-XA34888	20021031
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003038130	A2	20030508	WO 2002-US34888	20021031
WO 2003038130	A3	20040212		
WO 2003038130	C1	20040422		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:  
US 2001-335048P P 20011031  
US 2001-335183P P 20011102  
WO 2002-US34888 A 20021031

L10 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2002:832556 CAPLUS  
DOCUMENT NUMBER: 137:350862  
TITLE: Gene expression profiles in bone and cartilage formation and their use in diagnosis and treatment of disease  
INVENTOR(S): Clancy, Brian; Pittman, Debra M.  
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA  
SOURCE: PCT Int. Appl., 197 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085285	A2	20021031	WO 2002-US12149	20020418
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:  
US 2001-284786P P 20010418

L10 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2002:116539 CAPLUS  
 DOCUMENT NUMBER: 136:146231  
 TITLE: Nucleic acid compositions, kits, and methods for  
 identification, assessment, prevention, and therapy of  
 human breast cancer  
 INVENTOR(S): Lillie, James; Palermo, Adam; Wang, Youzhen;  
 Steinmann, Kathleen; Elias, Josh  
 PATENT ASSIGNEE(S): Millennium Predictive Medicine, Inc., USA  
 SOURCE: PCT Int. Appl., 2674 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001046697	A2	20010628	WO 2000-US35214	20001221
WO 2001046697	A3	20020110		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:  
 US 1999-171406P P 19991221  
 US 2000-176423P P 20000114  
 US 2000-190471P P 20000317  
 US 2000-193482P P 20000329  
 US 2000-205231P P 20000515  
 US 2000-213236P P 20000620  
 US 2000-219865P P 20000720

=> s leptin(w)receptor(w)(antisense or interfering)  
 L11 0 LEPTIN(W) RECEPTOR(W) (ANTISENSE OR INTERFERING)

=> s leptin(w)receptor and (antisense or interfering)  
 L12 53 LEPTIN(W) RECEPTOR AND (ANTISENSE OR INTERFERING)

=> dup rem  
 ENTER L# LIST OR (END):112  
 PROCESSING COMPLETED FOR L12  
 L13 31 DUP REM L12 (22 DUPLICATES REMOVED)

=> s l13 and py<2002  
 L14 13 L13 AND PY<2002

=> dis ti so au l14 1-13

L14 ANSWER 1 OF 13 MEDLINE on STN  
 TI Leptin inhibits steroid biosynthesis by human granulosa-lutein cells.  
 SO Hormone and metabolic research. Hormon- und Stoffwechselforschung.  
 Hormones et metabolisme, (2001 Jun) 33 (6) 323-8.  
 Journal code: 0177722. ISSN: 0018-5043.  
 AU Ghizzoni L; Barreca A; Mastorakos G; Furlini M; Vottero A; Ferrari B;  
 Chrousos G P; Bernasconi S

L14 ANSWER 2 OF 13 MEDLINE on STN  
 TI Distribution of galanin-like peptide in the rat brain.

SO Endocrinology, (2001 Apr) 142 (4) 1626-34.  
Journal code: 0375040. ISSN: 0013-7227.

AU Takatsu Y; Matsumoto H; Ohtaki T; Kumano S; Kitada C; Onda H; Nishimura O;  
Fujino M

L14 ANSWER 3 OF 13 MEDLINE on STN

TI Galanin-like peptide (GALP) is a target for regulation by leptin in the  
hypothalamus of the rat.

SO Endocrinology, (2000 Jul) 141 (7) 2703-6.  
Journal code: 0375040. ISSN: 0013-7227.

AU Jureus A; Cunningham M J; McClain M E; Clifton D K; Steiner R A

L14 ANSWER 4 OF 13 MEDLINE on STN

TI [Evaluating genetics and environment in development of obesity].  
Bewertung von Genetik und Umwelt fur die Entstehung von Ubergewicht.

SO Acta medica Austriaca, (1998) 25 (4-5) 129-30. Ref: 6  
Journal code: 7501997. ISSN: 0303-8173.

AU Lechleitner M; Hoppichler F

L14 ANSWER 5 OF 13 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

TI Galanin-like peptide mRNA in the hypothalamus is regulated by leptin.

SO Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract  
No.-440.10. print.  
Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New  
Orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.  
ISSN: 0190-5295.

AU Jureus, A. [Reprint author]; Cunningham, M. J.; McClain, M.; Clifton, D.  
K.; Steiner, R. A.

L14 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

TI Use of cDNAs encoding cytoplasmic domain of mouse and human Ob (leptin)  
receptors in diagnosis and treatment of body weight disorders

SO U.S., 49 pp., Cont.-in-part of U.S. Ser. No. 569,485, abandoned.  
CODEN: USXXAM

IN Tartaglia, Louis Anthony; Tepper, Robert I.; Culpepper, Janice A.

L14 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

TI Use of cDNAs encoding mouse and human Ob (leptin) receptors in diagnosis  
and treatment of body weight disorders

SO U.S., 75 pp., Cont.-in-part of U.S. Ser. No. 570,142, abandoned.  
CODEN: USXXAM

IN Tartaglia, Louis A.; Tepper, Robert I.; Culpepper, Janice A.

L14 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

TI Methods and compositions for control of bone formation via modulation of  
leptin activity

SO PCT Int. Appl., 142 pp.  
CODEN: PIXXD2

IN Karsenty, Gerard; Ducy, Patricia; Amling, Michael

L14 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

TI Human and murine isoforms of the Ob receptor and their use in methods of  
identifying compounds that modulate body weight

SO U.S., 88 pp., Cont.-in-part of U.S. Ser. No. 583,153.  
CODEN: USXXAM

IN Tartaglia, Louis A.; Tepper, Robert I.; Culpepper, Janice A.

L14 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

TI Cloning of cDNA for a human **leptin receptor** variant  
and methods for detecting variants and regulating obesity

SO PCT Int. Appl., 34 pp.  
CODEN: PIXXD2

IN Snodgrass, H. Ralph; Cioffi, Joseph; Zupancic, Thomas J.; Shafer, Alan W.

L14 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN



TI Cloning of cDNA for a human **leptin receptor** variant  
 and methods for detecting the variant and regulating obesity  
 SO PCT Int. Appl., 26 pp.  
 CODEN: PIXXD2  
 IN Snodgrass, H. Ralph; Cioffi, Joseph; Zupancic, Thomas J.; Shafer, Alan W.

L14 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN  
 TI Cloning of cDNA for db gene encoding the receptor for leptin and use of  
 the receptor  
 SO PCT Int. Appl., 171 pp.  
 CODEN: PIXXD2  
 IN Friedman, Jeffrey M.; Lee, Gwo-hwa; Proenca, Ricardo; Ioffe, Ella

L14 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN  
 TI Human **leptin receptor** variant and its detection and  
 therapeutic use  
 SO PCT Int. Appl., 26 pp.  
 CODEN: PIXXD2  
 IN Snodgrass, H. Ralph; Cioffi, Joseph; Zupancic, Thomas J.; Shafer, Alan W.

=> dis his

(FILE 'HOME' ENTERED AT 11:26:51 ON 01 SEP 2005)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE' ENTERED AT 11:27:12 ON 01 SEP 2005  
 E COUTURIER/AU

L1 0 S E18 AND E30  
 L2 0 S E18,30  
 L3 131 S E18  
 L4 147 S E18 OR E30  
 L5 93 DUP REM L4 (54 DUPLICATES REMOVED)  
 L6 1 S L5 AND LEPTIN AND ANTISENSE  
 L7 45 S OB-RGRP  
 L8 114357 S ANTISENSE OR SIRNA  
 L9 4 S L7 AND L8  
 L10 4 DUP REM L9 (0 DUPLICATES REMOVED)  
 L11 0 S LEPTIN(W)RECEPTOR(W) (ANTISENSE OR INTERFERING)  
 L12 53 S LEPTIN(W)RECEPTOR AND (ANTISENSE OR INTERFERING)  
 L13 31 DUP REM L12 (22 DUPLICATES REMOVED)  
 L14 13 S L13 AND PY<2002

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	75.18	75.39
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.73	-0.73

STN INTERNATIONAL LOGOFF AT 11:37:09 ON 01 SEP 2005